Cargando…

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL

Detalles Bibliográficos
Autores principales:	Jochems, Caroline, Kwilas, Anna, Kim, Young-Seung, Brechbiel, Martin W, Fantini, Massimo, Metenou, Simon, Fernando, Romaine I, Kim, Peter S, Gameiro, Sofia, Hodge, James, Newton, Robert, Schlom, Jeffrey, Tsang, Kwong Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649288/ http://dx.doi.org/10.1186/2051-1426-3-S2-P275

Ejemplares similares

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
por: Gangadhar, Tara C, et al.
Publicado: (2015)

Androgen deprivation therapy increases the sensitivity of human prostate carcinoma cells to T cell-mediated lysis through an androgen receptor dependent mechanism
por: Gameiro, Sofia, et al.
Publicado: (2014)

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
por: Gameiro, Sofia R., et al.
Publicado: (2016)

IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma
por: Buhe, Hada, et al.
Publicado: (2022)

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin
por: Kwilas, Anna R., et al.
Publicado: (2016)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Susceptibility of HBZ and Tax expressing primary HTLV-1+ T cell clones to CTL lysis
por: Rowan, Aileen G, et al.
Publicado: (2011)

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
por: Hodge, James W, et al.
Publicado: (2013)

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
por: Gameiro, Sofia R, et al.
Publicado: (2014)

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
por: Lee, Maxwell Y., et al.
Publicado: (2021)

Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis
por: Pardo, Julián, et al.
Publicado: (2004)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Gabitzsch, Elizabeth S., et al.
Publicado: (2015)

CADM1/TSLC1 Identifies HTLV-1-Infected Cells and Determines Their Susceptibility to CTL-Mediated Lysis
por: Manivannan, Kiruthika, et al.
Publicado: (2016)

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Sublethal exposure to alpha radiation ((223)Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
por: Malamas, Anthony S., et al.
Publicado: (2016)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
por: Ardiani, Andressa, et al.
Publicado: (2014)

Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes
por: Ogg, G S, et al.
Publicado: (2000)

A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model
por: Kwilas, Anna R., et al.
Publicado: (2015)

Suppression and Regression of Choroidal Neovascularization in Mice by a Novel CCR2 Antagonist, INCB3344
por: Xie, Ping, et al.
Publicado: (2011)

INCB, WHO AND UNODC STATEMENT ON ACCESS TO INTERNATIONALLY CONTROLLED MEDICINES DURING COVID-19 PANDEMIC
Publicado: (2020)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
por: Kim, Peter S., et al.
Publicado: (2016)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

SAT249 Femur Lysis Calcium Crisis
por: Gupta, Gunjan, et al.
Publicado: (2023)

The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
por: Leal, Ana S., et al.
Publicado: (2020)

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
por: Gameiro, Sofia R., et al.
Publicado: (2013)

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
por: Harding, James J., et al.
Publicado: (2023)

Broad CTL Response in Early HIV Infection Drives Multiple Concurrent CTL Escapes
por: Leviyang, Sivan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_175ktc7erntdasqm2tnqnpb087